Optiscan Imaging Limited announced submission of its FDA (United States Food and Drug Administration) Pre-Market Notification (510(k)) application for the InVivage® device intended for oral tissue imaging. InVivage® is a next generation, non-invasive, instantaneous form of oral imaging, targeting the severe health consequences of late-stage diagnosis of oral cancers and precancerous lesions. The technology platform enables real-time, non-destructive, 3D, in-vivo imaging at the sub-cellular level which aims to provide physicians, surgeons and pathologists with high resolution microscopic images intraoperatively that can be used to assist with diagnosis and treatment of various oral pathologies.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.105 AUD | +7.14% | -12.50% | +25.00% |
05-13 | Optiscan Imaging CEO to Host Mayo Clinic Agreement Webinar | MT |
03-21 | Optiscan Imaging Receives More Than AU$670,000 as R&D Tax Rebate | MT |
1st Jan change | Capi. | |
---|---|---|
+25.00% | 61.42M | |
+11.91% | 227B | |
+15.46% | 197B | |
+18.58% | 141B | |
+30.36% | 110B | |
+0.65% | 64.15B | |
+17.74% | 53.72B | |
+5.82% | 51.75B | |
+11.23% | 45.2B | |
+5.73% | 37.37B |
- Stock Market
- Equities
- OIL Stock
- News Optiscan Imaging Limited
- Optiscan Submits FDA 510(k) Application for InVivage Device